2019-03-20

[#DIV28SUPER] UVM NIH POSTDOCTORAL RESEARCH FELLOWSHIP POSITION


NIH Postdoctoral Research Fellowship Opportunity

 

The University of Vermont's Center on Behavior and Health announces an NIH postdoctoral research fellowship opportunity in our internationally recognized center of excellence for the study of substance abuse. The fellow will participate in the conduct of an ongoing NIDA/FDA-funded trials on the use of tobacco in vulnerable populations, including pregnant women, as well as develop new research opportunities in related areas. The mentoring team has an exceptional track record of helping fellows further their careers as independent investigators.

 

Eligibility: Applicants must have completed their training in psychology, behavior analysis, or a related discipline. Trainees are selected on the basis of scholastic record and commitment to a career in tobacco research. Individuals must be highly motivated, possess initiative and a desire to learn and expand their interests and expertise. Experience with behavioral economics is highly valued. There may be additional application requirements if you are a non-US citizen or non-permanent resident. Appointment:  2-3 yrs.

 

Benefits: Stipend, medical insurance coverage, and travel funds supported by NIH Institutional Training Awards.

 

To apply: Send application form (downloaded from VCBH website), a cover letter, curriculum vitae, statement of research interests, and 3 letters of reference to: Dr. Sarah Heil c/o Ms. Marissa Palmer (marissa.palmer@uvm.edu). 

 

About us: The VCBH was established in 2013, sponsored in part by a Centers of Biomedical Research Excellence (COBRE) Award from the National Institute on General Medical Sciences and a Centers of Tobacco Regulatory Science (TCORS) Award from the National Institute on Drug Abuse. The VCBH resides within the College of Medicine at the University of Vermont, with the director and administrative offices being located within the Department of Psychiatry, and participating investigators, collaborators, and advisors across 15 academic departments in the College of Medicine and 7 colleges within UVM and 5 other universities. The VCBH is further strengthened by interdisciplinary collaborations with key community healthcare leaders and distinguished scientific advisory panels. The focus of the VCBH is on investigating relationships between personal behaviors and risk for chronic disease and premature death, with a specific focus on understanding mechanisms underpinning risk, and developing effective interventions and policies to promote healthy behavior.

 

For more information:  Contact Ms. Marissa Palmer, marissa.palmer@uvm.edu or see our website.

 

Burlington, Vermont is located in the beautiful Lake Champlain region, surrounded by the Green and Adirondack Mountains. It is a great place for families, boasting excellent schools and year-round recreational opportunities. It is home to the University of Vermont and many other colleges that provide an academically stimulating and culturally rich environment. Montreal and Boston are within easy driving distances.


--

Stephen T. Higgins, Ph.D.
Director, Vermont Center on Behavior and Health
Virginia H. Donaldson Professor of Translational Science
Departments of Psychiatry and Psychological Science
Vice Chair, Department of Psychiatry
University of Vermont
1 South Prospect Street
Burlington, VT  05401-1419

VCBH Administrator: Marissa Palmer, MPH
marissa.palmer@uvm.edu
802-656-0079

_____________________________ div28SUPER@lists.apa.org
Div28m members may post here list archive
twitter: @apadiv28 #div28

2019-03-15

[#DIV28SUPER] The Science of Interoception and Its Roles in Nervous System Disorders, April 16-17, 2019, Sponsored by the NIH Blueprint for Neuroscience Research Workshop

You are invited to attend the NIH Blueprint for Neuroscience Research workshop, The Science of Interoception and Its Roles in Nervous System Disorders.

Information about the purpose, agenda, logistics and registration follows.

 

·       Home

·       Agenda

·       Logistics

·       Register Now

THE SCIENCE OF INTEROCEPTION AND ITS ROLES IN NERVOUS SYSTEM DISORDERS

NIH Blueprint Workshop

April 16-17, 2019
Lister Hill Auditorium, NLM (Building 38A)
Bethesda, MD

Workshop Objectives: The objective of this workshop is to identify gaps in research related to the science of interoception and its roles in nervous system disorders as well as to develop strategies and recommendations to facilitate the advancement of this area of research. The workshop will bring together expertise from diverse fields in basic neuroscience and clinical research to address two major connections – the connections between brain and body and the connections between basic research and human/clinical research. Areas of focus include: neural circuitry underlying the dynamic interactions between the central and peripheral nervous systems; Interoceptive processes in associated diseases and disorders; effect of modulating interoceptive processes and potential interventions/therapies; and development of technologies and methodologies to enhance interoceptive research.

Day 1

8:30 AM

Welcome Remarks and Introduction
Helene Langevin, Director of NCCIH

8:40 AM

Workshop Keynote:
Ardem Patapoutian, Scripps Research

9:10 AM

Session 1: Neural Circuits Underlying Communication Between the Brain and the Body
Session Chairs: Janine Simmons (NIMH); Peter Strick (University of Pittsburgh)
Rapporteur: Gary Berntson (Ohio State University)
Speakers:
Zachary A. Knight, University of California, San Francisco
Naomi I. Eisenberger, University of California, Los Angeles
Richard D. Lane, University of Arizona
Diego V. Bohorquez, Duke University

11:30 PM

Lunch

12:30 PM

Session 2: Dynamic and Functions of the Central and Peripheral Nervous Systems in Interoception
Session Chairs: Lis Nielsen and Coryse St. Hillaire-Clarke (NIA); Lisa Barrett (Northeastern University)
Rapporteur: Karen Quigley (Northeastern University)
Speakers:
Eliza Bliss-Moreau, University of California, Davis
Manos Tsakiris, University of London
Kyle Simmons, Johnson and Johnson
Scott Kanoski, University of Southern California

2:30 PM

Break

2:45 PM

Session 3: Modeling Disease, Alterations in Interoceptive Processes, and Comorbidities
Session Chairs: Changhai Cui (NIAAA); Rajita Sinha (Yale University)
Rapporteur: Bruno Bonaz (University of Grenoble, France)
Speakers:
Paul J. Kenny, Icahn School of Medicine at Mount Sinai
Rita J. Valentino, NIDA
Martin P. Paulus, Laureate Institute for Brain Research
Emeran A. Mayer, University of California, Los Angeles

4:45 PM

Wrap up of Day 1

5:00 PM

Adjourn

Day 2

8:45 AM

Workshop Keynote:
Hugo Critchley, Brighton and Sussex Medical School

9:15 AM

Session 4: Leveraging and Manipulating Interoception for Disease Intervention
Session Chairs: Victoria Spruance & Bonner, Joe (NIH/NICHD) ; Cynthia Price (University of Washington)
Rapporteur: Helen Weng (University of California, San Francisco)
Speakers:
Jack L. Feldman, University of California, Los Angeles
Lorenzo Leggio, NIAAA-NIDA
Jeanie Park, Emory University
Vitaly Napadow, Harvard University/Massachusetts General Hospital

11:30 PM

Lunch

12:30 AM

Session 5: Technologies, Methodologies, and Biomarkers for Interoception Research
Session Chairs: Jim Gnadt (NINDS); Christof Koch (Allen Brain Institute)
Rapporteur: Frederike Petzschner (University of Z├╝rich, Switzerland)
Speakers:
Rob W. Gereau, Washington University
Sarah Garfinkel, University of Sussex
Lisa Stowers, Scripps Research
Warren Grill, Duke University

2:30 PM

Break

2:45 PM

Session 6: Discussions - Future Directions & Recommendations
Session Chairs: Wen Chen (NCCIH), Dana Schloesser (OBSSR), and Angela Arensdorf (NCCIH)
Speaker:
Sahib Khalsa, Laureate Institute for Brain Research
Panelists: Gary Berntson, Karen Quigley, Bruno Bonaz, Helen Weng, Frederike Petzschner

4:45 PM

Wrap-up

5:00 PM

Adjourn

This site is created and hosted by The Scientific Consulting Group, Inc.

-----

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

2019-03-07

[#DIV28SUPER] Announcing a CounterACT Funding Opportunity Q&A Webinar

 

 

CounterACT Funding Opportunity Q&A

Informational Webinar

 

Wednesday, March 27, 2019

 

1:00 PM EST

 

CLICK HERE TO REGISTER AND JOIN THE WEBINAR

 

 

 

The NIH CounterACT program supports basic and translational research aimed at understanding the fundamental mechanisms of toxicity caused by chemical threat agents and the application of this knowledge to develop promising therapeutics for reducing mortality and morbidity caused by these agents. 

 

This NIH-led program includes a comprehensive network of Research Centers of Excellence, individual co-operative research projects, small business innovation research grants, contracts, and interagency agreements with the Department of Defense. 

 

We are hosting a free webinar to explain the current NIH CounterACT funding opportunity announcements (see links below), application best practices, support offered by the program, as well as answer questions from the audience.

 

 

PAR-18-721: Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21 Clinical Trial Not Allowed)

 

PAR-10-039: Countermeasures Against Chemical Threats (CounterACT): Identification of Therapeutic Lead Compounds (U01 Clinical Trial Not Allowed)

 

PAR-19-040: Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional)

 

PAR-18-657: Countermeasures Against Chemical Threats (CounterACT) Research Centers of Excellence (U54 Clinical Trial Optional)

 

 

You can also submit questions before the meeting to timothy.lyden@nih.gov While you can listen to the meeting by phone by dialing 1650-479-3209 Access Code 626 322 885, all questions will need to be submitted online.

 

Webinar will be led by the NIH CounterACT Program Director, David A. Jett, PhD.

 

 

Please feel free to forward to any people that may be interested.

 

 

 

 

Shardell M. Spriggs, PhD.

Program Manager, NIH CounterACT Program

Division of Translational Research

National Institute of Neurological Disorders and Stroke

Neuroscience Center, Room 2141A

6001 Executive Blvd.

Rockville, MD 20892

301.443.8189

shardell.spriggs@nih.gov

 

The National Institute on Drug Abuse at the National Institutes of Health is an agency of the United States Department of Health and Human Services  TO UNSUBSCRIBE: send email to listserv@list.nih.gov Copy and paste UNSUBSCRIBE NIDA_NEURO_SCIENCE-L   in the message body of the email - You will receive a confirmation email if successful. If you have problems contact jpollock@mail.nih.gov   301-435-1309

 

2019-03-05

[#DIV28SUPER] Post-Doctoral Fellowship at the University of Kentucky

Post-Doctoral Fellowship

** Available July 1, 2019 ***

The University of Kentucky College of Medicine Department of Behavioral Science is seeking applicants for a post-doctoral fellowship. This is a two-year fellowship, with an optional third year, funded by National Institute on Drug Abuse (NIDA) T32 that is designed to train researchers in behavioral aspects of substance use disorders. The fellowship also provides ample opportunity for professional development, including grant writing and enhancing presentation and publication skills. Applicants should be highly motivated, have recently obtained a doctorate in psychology, pharmacology or a related discipline and must be a U.S. citizen or permanent resident. The fellowship includes salary, tuition (if applicable) and expenses for travel to conferences.  

For further application details, please email Dr. Craig Rush (crush2@uky.edu). Applications are due April 15, 2019.



               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383


Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

Interim Director
Clinical Research Support Office

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2019-02-28

[#DIV28M] note to graduate students - are you doing research on opioids?

If you are a graduate student doing work on opioids for your thesis or dissertation, please let me know.

Best info would be: 

name:
contact info:
state:
title of research:
supervisor or mentor name:
brief description:


Send info back channel rather than to the whole list.

Again, I am trying to shine a light on what we are collectively doing.

thanks in advance.

Please respond no later than Sunday.


Nancy A. Piotrowski, Ph.D.
Core Faculty & Lead, Addiction Psychology
Harold Abel School of Social of Psychology
Capella University
 
Federal Advocacy Coordinator, Society of Addiction Psychology, Div50, American Psychological Association
Council Representative & Membership Chair, Society of Environmental, Population, & Conservation Psychology, Div34, American Psychological Association
Past President, Napa Solano Psychological Association
Member, Public Education Committee, California Psychological Association

 
MAIL:  P.O. Box 5525, Vallejo, California 94591-0552
With Offices in the San Francisco Bay Area
Text or Message:  707.561.2358
Call or Message:  415.386.4923
FAX by request
 
Email:              napiotrowski@yahoo.com    
ALT Email:       PiotrowskiConsultation@gmail.com
Skype:             napiotrowski
 

IMPORTANT NOTICE: This transmission and any attachments are intended only for the individual or entity to which it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable federal or state laws.  If the reader of this transmission is not the intended recipient, you are hereby notified that any use, dissemination, distribution or copying of this communication, without explicit written communication to handle otherwise, is strictly prohibited.  If you have received this transmission in error, please notify me immediately by email.

[#DIV28SUPER] special issue of NTR

Impact of Cannabis Use on Nicotine and Tobacco Use Outcomes

Call for Submissions

Nicotine & Tobacco Research intends to publish a themed issue on the impact of cannabis use on tobacco use outcomes. Guest editors will be Renee Goodwin and Gillinder Bedi.

The aim of the proposed themed issue is to bring together the most recent, cutting-edge work that addresses the potential influence of cannabis use on use of the range of nicotine and tobacco products. This can include studies that address this issue using data from animal model, human laboratory, clinical treatment, policy, health services and population health studies.

In addition to submissions focusing directly on the influence of cannabis use on various forms of nicotine and tobacco use (including transitions in use such as initiation, cessation, and relapse), we invite submission of studies that examine co-use via newer nicotine and tobacco products where there are direct implications for tobacco use outcomes (e.g., initiation of co-use leading to regular tobacco use). We are also interested in studies that examine puff topography, brand of tobacco, type of tobacco; amount of use; the mechanisms of the relationship between cannabis and tobacco use (e.g., reinforcing effect, complementarity, substitution); and patterns of how cannabis use impacts tobacco use over time (e.g., EMA and longitudinal studies).

Submissions focusing on a range of outcomes (e.g., initiation, cessation) and products (e.g., cigarettes, ENDS, etc.), and work that examines the biological, social and cultural pathways through which cannabis may impact use of nicotine and tobacco are encouraged.

Examples of possible manuscript topics include, but are not limited to:

  • Epidemiological studies examining the impact of cannabis use on the range of nicotine and tobacco use outcomes over time among youth and adults.
  • Laboratory studies examining nicotine and tobacco outcomes.
  • Randomized clinical trials of cessation interventions for nicotine and tobacco users with cannabis use and/or cannabis use disorder.

Manuscripts must be submitted through the Nicotine & Tobacco Research submission system (https://mc.manuscriptcentral.com/ntr) by May 31, 2019. We anticipate that the themed issue will be published in mid-2020.

Submission of a manuscript does not guarantee its acceptance. All manuscripts will be reviewed by the Nicotine & Tobacco Research editorial staff and referees, and must meet the standards for publication in Nicotine & Tobacco Research.

Nicotine & Tobacco Research home page and instructions for authors: https://academic.oup.com/ntr

For any questions, please contact the guest editors: Renee Goodwin (renee.goodwin@sph.cuny.edu) and Gillinder Bedi (gill.bedi@orygen.org.au).



               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383


Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

Interim Director
Clinical Research Support Office

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.

2019-02-23

[#DIV28SUPER] Update from Council

Dear Division 28 Colleagues-
I have attached a summary of activities from last weekend's APA Council meeting. The psychopharmacology curriculum changes may be especially of interest. Please let me know if you have any questions about this information.
-Bill Stoops, Division 28 Council Representative

               
---------------------------------------------------------------------------------
William W. Stoops, Ph.D.
email: william.stoops@uky.edu
telephone: (859) 257-5383


Professor
University of Kentucky College of Medicine
Department of Behavioral Science
Department of Psychiatry
Center on Drug and Alcohol Research
University of Kentucky College of Arts and Sciences
Department of Psychology

Director
Regulatory Knowledge and Support Core
University of Kentucky Center for Clinical and Translational Science

Interim Director
Clinical Research Support Office

STATEMENT OF CONFIDENTIALITY
The contents of this e-mail message and any attachments are confidential and are intended solely for the addressee. The information may also be legally privileged. This transmission is sent in trust, for the sole purpose of delivery to the intended recipient. If you have received this transmission in error, any use, reproduction or dissemination of this transmission is strictly prohibited. If you are not the intended recipient, please immediately notify the sender by reply e-mail or at (859) 257-5383 and delete this message and its attachments, if any.